METHODS OF CELL CULTURE FOR ADOPTIVE CELL THERAPY

• US 20130115617A1
• Filed: 06/11/2012
• Published: 05/09/2013
• Est. Priority Date: 12/08/2009
• Status: Abandoned Application

• Current Assignee: Baylor College of Medicine (Baylor College), Wilson Wolf Manufacturing Corporation
• Original Assignee: Baylor College of Medicine (Baylor College)
• Inventors: Wilson, John R.
• Application Number:
  US13/493,768
• Publication Number:
  US 20130115617A1
• Time in Patent Office: Days
• US Class Current: 435/7.1
• CPC Class Codes: A61K 2039/55516 Proteins; Peptides
• CPC Class Codes: A61K 2039/55527 Interleukins
• CPC Class Codes: A61K 2039/55533 IL-2
• CPC Class Codes: A61K 2239/26 Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
• CPC Class Codes: A61K 2239/48 Blood cells, e.g. leukemia or lymphoma
• CPC Class Codes: A61K 2239/58 Prostate
• CPC Class Codes: A61K 39/39 characterised by the immunostimulating additives, e.g. chemical adjuvants
• CPC Class Codes: A61K 39/4611 T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
• CPC Class Codes: A61K 39/4621 immunosuppressive or immunotolerising
• CPC Class Codes: A61K 39/4631 Chimeric Antigen Receptors [CAR]
• CPC Class Codes: A61K 39/46433 Antigens related to auto-immune diseases; Preparations to induce self-tolerance
• CPC Class Codes: A61K 39/46434 Antigens related to induction of tolerance to non-self
• CPC Class Codes: A61K 39/464493 Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
• CPC Class Codes: A61K 39/464838 Viral antigens
• CPC Class Codes: A61K 48/0033 the non-active part being non-polymeric
• CPC Class Codes: A61K 51/08 Peptides, e.g. proteins , carriers being peptides, polyamino acids, proteins
• CPC Class Codes: A61K 9/5068 Cell membranes or bacterial membranes enclosing drugs with additional exogenous lipids A61K9/127; virus envelopes A61K9/5184
• CPC Class Codes: C07K 14/7051 T-cell receptor (TcR)-CD3 complex
• CPC Class Codes: C07K 2319/03 containing a transmembrane segment
• CPC Class Codes: C12M 23/24 Gas permeable parts
• CPC Class Codes: C12N 15/115 : Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
• CPC Class Codes: C12N 2310/16 : Aptamers
• CPC Class Codes: C12N 2320/32 : Special delivery means, e.g. tissue-specific
• CPC Class Codes: C12N 2502/11 : blood or immune system cells
• CPC Class Codes: C12N 2502/1107 : B cells
• CPC Class Codes: C12N 5/0636 : T lymphocytes
• CPC Class Codes: C12N 5/0638 : Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]

Abstract

Production and use of novel therapeutic cells, called T-Vehicles, in the allogeneic Adoptive Cell Therapy setting allows a wide range of therapeutic benefits to accrue with minimal or no risk of GVHD. T-Vehicles are created from donor T cells that are altered to contain therapeutic attributes that do not include their native antigen receptors and can deliver therapeutic benefits irrelevant of their native antigen specificity. T-Vehicles can possess highly restricted native antigen specificity that renders them unable to recognize antigens present on normal cells and incapable of initiating GVHD, making them ideal transport vehicles to deliver various therapeutic attributes in vivo. In essence, production and use of T-Vehicles is a paradigm shift that opens the door to therapeutic application of T cells in ways not previously contemplated, independent of whether or not there is an HLA match between the donor and the recipient.

Claims

1. (canceled)

2. (canceled)

3. A method for creating a desired population of antigen specific T cells, the method comprising:

A. Initiating the culture of antigen specific T cells with desired antigen recognition by placing PBMCs or cord blood into a cell culture device,

B. Adding more than one antigen into said cell culture device in order to activate the growth of more than one population of antigen specific T cells, each population capable of recognizing one of said antigens,

C. Allowing a period of time for said antigen specific T cells to initiate population expansion,

D. Assessing the culture to determine the presence and/or quantity of at least one population of antigen specific T cells,

E. Determining which of the populations of T cells is suitable for continued proliferation, and

F. Re-stimulating the culture only with antigens recognized by said suitable populations of T cells.